COVID-19 Human IgM IgG ELISA kit (Spike Protein)

96T ¥150,000

​(税別)

​※ 正規代理店ページへ移動します

​在庫:あり

Manual

​SDS

Flyer

Specification

Measurement method:   Indirect ELISA

Measurement wavelength:   450 nm

Measurement sample:   Serum

Species reactivity:    Human

Storage temperature:   Keep HRP-conjugated anti-human IgM/IgG antibody at or below -20 ° C. 

                                     Keep other reagents and immobilized plate at 2-8 ° C

Expiration date:   This product is valid for 5 months after production.

Immobilized antige:   SARS-CoV-2 spike protein (S1+S2 domain, mammalian expression system)

Kit contents

1. SARS-CoV-2 spike protein-immobilized plate

2. HRP-conjugated anti-human IgM antibody

3. HRP-conjugated anti-human IgG antibody

4. Washing buffer(10× PBST)

5. Non-fat milk (for blocking buffer)

6. Diluent buffer (10×)

7. R-1: Chromogenic substrate (TMB)

8. R-2: Stop reagent (1 mol/L hydrochloric acid)

9. Microplate seal

×2

10 μL×1

10 μL×1

50 mL×2

×1

50 mL×1

10 mL×2

10 mL×2

×2

Measurement principle

  1. The immobilized SARS-CoV-2 recombinant spike protein on a plate is reacted with the antibody (hereinafter referred to as anti-spike protein antibody) in a sample that recognizes it.

  2.  After the reaction, the sample is removed by washing.

  3.  React anti-spike protein antibody in the plate with HRP (horseradish peroxidase)- conjugated anti-human  IgM / IgG antibodies.

  4. Remove excess HRP-conjugated anti-human IgM / IgG antibodies by washing. Add a chromogenic substrate and measure the absorbance.

Significance of measurement

This kit is a research ELISA kit to detect human IgM and IgG antibodies that recognize the spike protein of SARS-CoV-2, the causative virus of Covid-19.

Virus detection can be broadly divided into two approaches: one is to detect the virus itself, such as PCR method, and the other is to detect the immune response that develops during infection (IgG, IgM, IgA). In common infections, IgM is an antibody produced early in the infection and disappears with relief of symptoms. IgG begins to be produced later than IgM and continues to be produced for months after healing. This is known to reduce the symptoms of the next infection or to prevent the onset of the next infection

Related literature

      BMJ. 2020 Jul. PubMed PMID: 32611558

      J Clin Virol. 2020 Aug. PubMed PMID: 32563180

      Emerg Microbes Infect. 2020 Dec. PubMed PMID: 32357808

      Lancet. 2020 13-19 June. PubMed PMID: 32450106

      Emerg Microbes Infect. 2020 Jun 12. PubMed PMID: 32529906

      Sci Immunol. 2020 Jun 11. PubMed PMID: 32527802

      Nat Med. 2020 Jun 5. PubMed PMID: 32504052​

      Science. 2020 Jun 5. PubMed PMID: 32414781​​

      Nat Commun . 2020 Jun 1. PubMed PMID: 32483236​

      Curr Protoc Microbiol. 2020 Jun. PubMed PMID: 32302069

      Cell Mol Immunol. 2020 May 28. PubMed PMID: 32467617​​

      J Clin Microbiol. 2020 Jun. PubMed PMID: 32277023

      Clin Microbiol Infect. 2020 May. PubMed PMID: 32473953

     Viruses. 2020 May 26. PubMed PMID: 32466458

      J Clin Microbiol . 2020 May 26. PubMed PMID: 32229605​

      Sci China Life Sci. 2020 May. PubMed PMID: 32270436

      Cell. 2020 May 20. PubMed PMID: 32473127

     J Infect. 2020 May 15. PubMed PMID: 32417311

      J Clin Virol. 2020 Jul (Published online 2020 May 13.) PubMed PMID: 32434708

      J Med Virol. 2020 Apr 28. PubMed PMID: 32343415

      JAMA. 2020 Apr 28. PubMed PMID: 32219428

      Clin Chim Acta. 2020 Aug. PubMed PMID: 32343948

      Emerg Infect Dis. 2020 Apr 8. PubMed PMID: 32267220

References

1.)Keiichi Hiramatsu, Standard Textbook of standard microbiology, 11th edition, Medical study (2012)

2.)Anu Haveri , “Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland,” January to February 2020 , Eurosurveillance.  Volume 25, Issue 11, 19, Mar 2020.

3.)Wanbing Liu, “Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2”, J Clin Microbiol. 2020 Mar 30.

4.)Li Guo, “Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)”, Clin Infect Dis. 2020 Mar 21.

5.)Juanjuan Zhao, “Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019”, Clin Infect Dis. 2020 Mar 21.

Cellspect Co., Ltd.

〒020-0857

2-4-23 Kitaioka, Morioka, Iwate Prefecture

TEL : +81 19-681-6710 / FAX  : +81 19-903-0418

MAIL : info@cellspect.com

URL : https://cellspect.com

COVID-19 Related Products

TEL : +31 3-5825-3557

MAIL : info@berthold-jp.com

Berthold Japan Co., Ltd.

COVID-19 Related Interviews

TEL : +81 19-134-6616

MAIL : support@cellspect.com

Copyright ©2018 cellspect All Rights Reserved. Wix.comで作成したホームページです。